Does NHS Improvement (NHSI) provide a definition for central line-associated bloodstream infection (CLABSI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 22, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Does NHSI Define CLABSI?

No, NHS Improvement (NHSI) does not provide its own definition for CLABSI; instead, international guidelines consistently recommend using the CDC/NHSN (Centers for Disease Control and Prevention/National Healthcare Safety Network) uniform surveillance methods and definitions for CLABSI surveillance. 1

Standard CLABSI Definition Source

  • The CDC/NHSN definition is the internationally recognized standard that should be employed for CLABSI surveillance, including in UK healthcare settings where NHSI operates. 1

  • The CDC defines CLABSI as a primary bloodstream infection in a patient who had a central venous catheter within 48 hours before infection onset, with no other identifiable source of infection. 2, 3, 4

  • When the interval between infection onset and device use exceeds 48 hours, compelling evidence must link the infection to the central line. 3, 5

Why CDC/NHSN Definitions Are Universal

  • International guidelines explicitly direct healthcare facilities to employ CDC/NHSN uniform surveillance methods and definitions rather than developing institution-specific or country-specific criteria. 1

  • The International Society for Infectious Diseases 2024 update mandates that establishments implementing CLABSI prevention must have an infection prevention team tasked with identifying patients who meet the CLABSI definition using these standardized criteria. 1

  • CLABSI rates should be calculated by dividing the number of CLABSIs by total central line-days, then multiplying by 1,000, following CDC/NHSN methodology. 1

Important Distinction: CLABSI vs CRBSI

  • CLABSI is a broader epidemiological surveillance definition used for infection control monitoring, while CRBSI (catheter-related bloodstream infection) requires definitive microbiological evidence that the catheter is the infection source. 2

  • The CDC/NHSN uses CLABSI for surveillance purposes, but this may overestimate true catheter-related infections and should not solely guide individual patient management decisions without CRBSI confirmation. 2

  • CRBSI diagnosis requires either positive catheter tip culture (≥15 CFU by semiquantitative method or ≥10² CFU by quantitative method) with matching peripheral blood culture, or paired quantitative blood cultures with a ratio ≥3:1 (catheter to peripheral). 2, 3

Practical Implications for UK Practice

  • UK facilities should implement the CDC/NHSN CLABSI definition for surveillance and benchmarking, as this allows international comparison and aligns with evidence-based prevention bundles. 1

  • The negative predictive value of CDC/NHSN criteria is excellent (97.1%), making it reliable for screening purposes. 6

  • Modified or institution-specific CLABSI definitions have been tested but have not proven superior to CDC/NHSN criteria and may complicate benchmarking efforts. 6, 7

Related Questions

What are the CLABSI (Central Line-Associated Bloodstream Infection) attribution rules for boarding ICU (Intensive Care Unit) patients in the CDC (Centers for Disease Control and Prevention)/NHSN (National Healthcare Safety Network) guidelines?
What are the recommended strategies for preventing and treating central line‑associated bloodstream infections (CLABSI) in patients with a central venous catheter?
What is the treatment approach for Central Line-Associated Bloodstream Infections (CLABSI) versus Catheter-Related Bloodstream Infections (CRBSI)?
What is the management approach for Central Line-Associated Bloodstream Infections (CLABSI)?
What are the prevention and management strategies for Central Line-Associated Bloodstream Infections (CLABSI)?
What is Gilbert syndrome and how is it managed?
For an adult with obesity (body mass index ≥ 30 kg/m² or ≥ 27 kg/m² with weight‑related comorbidities) and no type 2 diabetes, how should retatrutide be initiated, titrated, monitored, and what are its efficacy and safety profile?
What should I do about my elevated plasma vitamin B6 (pyridoxine) level?
How should hypertriglyceridemia be evaluated and managed, including lifestyle modifications, medication indications, and follow‑up?
I have markedly elevated serum vitamin B2 (riboflavin) levels despite not taking any B‑vitamin supplements, fortified foods, or energy drinks; what could be causing this elevation and how should I evaluate and manage it?
What is the recommended management for hypertriglyceridemia, including lifestyle modifications and pharmacologic therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.